Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SYPRINE (trientine hydrochloride) is an oral small-molecule chelating agent approved in 1985 for Wilson's disease, a rare genetic disorder of copper metabolism. It binds excess copper and facilitates urinary excretion, reducing toxic copper accumulation in organs. The drug serves patients who cannot tolerate penicillamine, the first-line therapy.
Niche rare-disease product with minimal commercial footprint and flat spend, suggesting small, specialized teams focused on patient retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SYPRINE offers limited career momentum in a niche rare-disease segment with minimal hiring and declining commercial value as LOE approaches. Professionals assigned to this product should view it as a stabilization or specialty expertise role rather than a high-growth opportunity.
Worked on SYPRINE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo